Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Androgen Receptor
    (1)
  • Apoptosis
    (16)
  • Autophagy
    (4)
  • DNA/RNA Synthesis
    (2)
  • Epigenetic Reader Domain
    (110)
  • HIV Protease
    (4)
  • Histone Acetyltransferase
    (13)
  • Histone Methyltransferase
    (12)
  • PROTACs
    (10)
  • Others
    (2)
Filter
Search Result
Results for "Epigenetic Reader Domain" in TargetMol Product Catalog
  • Inhibitor Products
    112
    TargetMol | Activity
  • PROTAC Products
    13
    TargetMol | inventory
  • Natural Products
    2
    TargetMol | natural
  • Recombinant Protein
    1
    TargetMol | composition
VTP50469
T133362169916-18-9
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.
  • $177
In Stock
Size
QTY
TargetMol | Inhibitor Hot
ARV-771
T54351949837-12-0
Glycodeoxycholic Acid is an endogenous metabolite, a natural product found in Streptomyces niger, Trypanosoma brucei, and Cryptomonas, which induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis.
  • $55
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Curcumin
T1516458-37-7
Curcumin (Natural Yellow 3) is a phenolic natural product, an inhibitor of histone acetyltransferase p300/CREB (IC50=25 μM) with specificity. Curcumin has a wide range of pharmacological activities such as antitumor, anti-inflammatory and antioxidant.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
SNDX-5613
T129432169919-21-3
SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias.
  • $67
In Stock
Size
QTY
TargetMol | Inhibitor Hot
(+)-JQ-1
T21101268524-70-4
(+)-JQ-1 (JQ1) is a BET bromine domain inhibitor that inhibits BRD4 (1/2) (IC50=77/33 nM) with specificity and reversibility. (+)-JQ-1 induces cell autophagy and inhibits cell proliferation.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
666-15
T53181433286-70-4
666-15 (CREB inhibitor) is a potent and selective CREB inhibitor (IC50: 81 nM).
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Naphthol AS-E
T785692-78-4
Naphthol AS-E (nAS-E) is an the KIX-KID interaction and CREB-mediated gene transcription inhibitor.
  • $33
In Stock
Size
QTY
UNC926 hydrochloride
T92211782573-49-2
UNC926 hydrochloride is a methyl-lysine (Kme) reader domain inhibitor.
  • $133
In Stock
Size
QTY
NHWD-870
T365732115742-03-3In house
NHWD-870 is an effective and selective inhibitor of BET family bromodomain only binding to BRD2, BRD3, BRD4 (IC50 = 2.7 nM), and BRDT. NHWD-870 exhibits potent anti-tumor efficacies and suppresses cancer cell-macrophage interaction through the increase of tumor apoptosis and inhibition of tumor proliferation.
  • $1,630
8-10 weeks
Size
QTY
TargetMol | Inhibitor Sale
CeMMEC1
T4345440662-09-9In house
CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Y06137
T133632226534-49-0In house
Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.
  • $55
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ABBV-744
T46972138861-99-9In house
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS.
  • $39
In Stock
Size
QTY
NEO2734
T86582081072-29-7In house
NEO2734 (EP31670) is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).
  • $116
In Stock
Size
QTY
SGC-CBP30
T66681613695-14-9
SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).
  • $45
In Stock
Size
QTY
TargetMol | Citations Cited
A-366
T36241527503-11-2
A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
I-BET151
T21201300031-49-5
I-BET151 (GSK1210151A) (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays).
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
BI-7273
T67831883429-21-7
BI-7273 is an effective, specific, BRD9 BD Inhibitor, which can infiltrate cell.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
BI 2536
T6173755038-02-9
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
  • $38
In Stock
Size
QTY
TargetMol | Citations Cited
MS402
T121121672684-68-2
MS402 is a novel BD1-selective BET BrD inhibitor.
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GSK8573
T154411693766-04-9
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ODM-207
T105211801503-93-4
ODM-207 (BET-IN-4) is a potent BRD4 inhibitor.
  • $68
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MI-136
T68891628316-74-4
MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BRD4 Inhibitor-10
T147761660117-38-3
BRD4 Inhibitor-10 is an inhibitor of BRD4-BD1 (IC50: 8 nM).
  • $67
In Stock
Size
QTY
TargetMol | Inhibitor Sale
I-CBP112 hydrochloride
T42472147701-33-3
I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains. I-CBP112 targets the CBP/p300 bromodomains. I-CBP112 significantly reduced the leukemia-initiating poten
  • $83
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BRM/BRG1 ATP Inhibitor-2
T600322368900-77-8
BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.
  • $57
In Stock
Size
QTY
TargetMol | Inhibitor Sale
RVX-297
T286281044871-04-6
RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.
  • $84
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FL-411
T43652118944-88-8
FL-411 (BRD4-IN-1) is a potent and selective BRD4 inhibitor with an IC50 of 0.43±0.09 μM for BRD4.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
NI-42
T163211884640-99-6
NI-42 is a structurally orthogonal chemical probe for the BRPFs and is biased. It effective inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM). It also has excellent selectivity over nonclass IV BRD protei
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BRD4 degrader AT1
T54392098836-45-2
BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.
  • $1,100
35 days
Size
QTY
TargetMol | Inhibitor Sale
BAZ1A-IN-1
T9552941521-45-5
BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.
  • $98
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BRD4 Inhibitor-24
T9629309951-18-6
BRD4 Inhibitor-24 is a BRD4 small molecule inhibitor with antitumor activity.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GSK-5959
T1972901245-65-6
GSK-5959 is an effective, specific and cell permeable BRPF1 bromodomain inhibitor (IC50: ~80 nM). The selectivity of GSK-5959 for BRPF1 is >100-fold over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains.
  • $52
In Stock
Size
QTY
XD14
T199351370888-71-3
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
  • $43
In Stock
Size
QTY
PFI-1
T62221403764-72-6
PFI-1 (PF-6405761), a specific BET (bromodomain-containing protein) inhibitor for BRD4, is with the IC50 of 0.22 μM in a cell-free assay.
  • $43
In Stock
Size
QTY
GSK778
T97032451862-42-1
GSK778 is a potent and selective inhibitor of BD1 bromodomain such as BRD2 BD1 (IC50s = 75 nM), BRD3 BD1 (IC50s = 41 nM), BRD4 BD1 (IC50s = 41 nM), and BRDT BD1 (IC50s = 143 nM). GSK778 inhibits proliferation, induces a cell cycle arrest and apoptosis.
  • $163
In Stock
Size
QTY
BRM/BRG1 ATP Inhibitor-1
T106162270879-17-7
BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).
  • $417
In Stock
Size
QTY
TargetMol | Citations Cited
EML 425
T152161675821-32-5
EML 425 is a potent and selective inhibitor of CREB binding protein (CBP)/p300 (IC50s: 2.9 and 1.1 μM, respectively).
  • $38
In Stock
Size
QTY
UNC926
T40121184136-10-4
UNC926 (UNC-926) inhibits L3MBTL1 (IC50: 3.9 μM). UNC926 also exhibits a low micromolar affinity for L3MBTL3. UNC926 inhibits binding of the 3xMBT domain to H4K20me1. It selectively and dose-dependently inhibits the L3MBTL13xMBT-H4K20me1 interaction. UNC926 has not an effect on the binding of 53BP1 to H4K20me1.
  • $31
In Stock
Size
QTY
GSK046
T89322474876-09-8
GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively). It has immunomodulatory activity.
  • $115
In Stock
Size
QTY
PF-CBP1 hydrochloride
T32172070014-93-4
PF-CBP1 hydrochloride (PF-CBP1 HCl) is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively.
  • $39
In Stock
Size
QTY
Mivebresib
T37121445993-26-9
Mivebresib (ABBV-075), also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD)-containing protein) with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.
  • $53
In Stock
Size
QTY
MS436
T18541395084-25-9
MS436 is a selective, small-molecule inhibitor for the BRD4 bromodomains.
  • $37
In Stock
Size
QTY
UMB298
T91942266569-73-5
UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. UMB298 inhibits BRD4 with IC50 of 5193nM.
  • $118
In Stock
Size
QTY
ARV-825
T54341818885-28-7
ARV-825, a heterobifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon leading to fast, efficient, and prolonged degradation of BRD4 in all BL cell lines tested.
  • $60
In Stock
Size
QTY
dBET6
T51301950634-92-0
dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity.
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
INCB-057643
T54171820889-23-3
INCB057643 is a potent, selective and orally bioavailable BET inhibitor.
  • $68
In Stock
Size
QTY
GNE-781
T154051936422-33-1
GNE-781 is a highly potent and selective inhibitor of CBP (IC50: 0.94 nM in TR-FRET assay). GNE-781 also inhibits BRET and BRD4(1) (IC50s: 6.2 nM and 5100 nM, respectively).
  • $166
In Stock
Size
QTY
OF-1
T2127919973-83-4
OF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain.
  • $35
In Stock
Size
QTY
PFI-3
T69391819363-80-8
PFI-3 is a selective chemical inhibitor for SMARCA (2/4) (Kd = 89 nM)and PBI (5) bromodomains which may result in the delay and prevention of breast cancer.
  • $32
In Stock
Size
QTY
I-CBP112
T39691640282-31-0
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor targeting the CBP/p300 bromodomains.
  • $51
In Stock
Size
QTY